Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer.

Anwer K, Kelly FJ, Chu C, Fewell JG, Lewis D, Alvarez RD.

Gynecol Oncol. 2013 Oct;131(1):169-73. doi: 10.1016/j.ygyno.2013.07.081. Epub 2013 Jul 14. Erratum in: Gynecol Oncol. 2014 Jul;134(1):216.

PMID:
23863356
2.

Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.

Strauss HG, Henze A, Teichmann A, Karbe I, Baumgart A, Thomssen C, Koelbl H.

Gynecol Oncol. 2007 Mar;104(3):612-6. Epub 2006 Oct 27.

PMID:
17069876
3.

A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).

Cognetti F, Bagnato A, Colombo N, Savarese A, Scambia G, Sehouli J, Wimberger P, Sorio R, Harter P, Mari E, McIntosh S, Nathan F, Pemberton K, Baumann K.

Gynecol Oncol. 2013 Jul;130(1):31-7. doi: 10.1016/j.ygyno.2012.12.004. Epub 2012 Dec 9.

PMID:
23234805
4.

Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer.

Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD.

Gene Ther. 2010 Mar;17(3):360-9. doi: 10.1038/gt.2009.159. Epub 2009 Dec 24.

PMID:
20033066
5.

A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study.

Alvarez RD, Sill MW, Davidson SA, Muller CY, Bender DP, DeBernardo RL, Behbakht K, Huh WK.

Gynecol Oncol. 2014 Jun;133(3):433-8. doi: 10.1016/j.ygyno.2014.03.571. Epub 2014 Apr 4.

6.

A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.

Alvarez Secord A, Berchuck A, Higgins RV, Nycum LR, Kohler MF, Puls LE, Holloway RW, Lewandowski GS, Valea FA, Havrilesky LJ.

Cancer. 2012 Jul 1;118(13):3283-93. doi: 10.1002/cncr.26610. Epub 2011 Nov 9.

7.

Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial.

Pokrzywinski R, Secord AA, Havrilesky LJ, Puls LE, Holloway RW, Lewandowski GS, Higgins RV, Nycum LR, Kohler MF, Revicki DA.

Gynecol Oncol. 2011 Dec;123(3):505-10. doi: 10.1016/j.ygyno.2011.08.015. Epub 2011 Sep 25.

PMID:
21945310
8.

A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.

Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP, Matei DE.

Cancer. 2010 Sep 1;116(17):4043-53. doi: 10.1002/cncr.25204.

9.

Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).

Koinis F, Polyzos A, Christopoulou A, Zafeiriou Z, Emmanouilidis C, Papadimitraki E, Kalykaki A, Kalbakis K, Samonis G, Georgoulias V.

Cancer Chemother Pharmacol. 2014 Apr;73(4):819-25. doi: 10.1007/s00280-014-2411-2. Epub 2014 Feb 15.

PMID:
24531559
10.

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB; Scottish Gynaecological Cancer Trials Group.

J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91.

11.

Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.

Sorbe B, Graflund M, Horvath G, Swahn M, Boman K, Bangshöj R, Lood M, Malmström H.

Int J Gynecol Cancer. 2012 Jan;22(1):47-53. doi: 10.1097/IGC.0b013e318234fa3a.

PMID:
22193643
12.

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.

del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T.

Gynecol Oncol. 2012 Sep;126(3):369-74. doi: 10.1016/j.ygyno.2012.05.028. Epub 2012 May 30.

PMID:
22659190
13.

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer.

Vasey PA, Atkinson R, Coleman R, Crawford M, Cruickshank M, Eggleton P, Fleming D, Graham J, Parkin D, Paul J, Reed NS, Kaye SB.

Br J Cancer. 2001 Jan;84(2):170-8.

14.

Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.

Taylor SE, Beck TL, Krivak TC, Zorn KK, Kelley JL, Edwards RP.

Gynecol Oncol. 2014 Jul;134(1):68-72. doi: 10.1016/j.ygyno.2014.04.039. Epub 2014 Apr 24.

PMID:
24769036
15.

Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.

Nagao S, Iwasa N, Kurosaki A, Nishikawa T, Ohishi R, Hasegawa K, Goto T, Fujiwara K.

Int J Gynecol Cancer. 2012 Jan;22(1):70-5. doi: 10.1097/IGC.0b013e318234f927.

PMID:
22146766
16.

Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.

Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL.

Gynecol Oncol. 2013 Jun;129(3):452-8. doi: 10.1016/j.ygyno.2013.03.002. Epub 2013 Mar 6.

PMID:
23474348
17.

A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.

Kimball KJ, Numnum TM, Kirby TO, Zamboni WC, Estes JM, Barnes MN, Matei DE, Koch KM, Alvarez RD.

Gynecol Oncol. 2008 Oct;111(1):95-101. doi: 10.1016/j.ygyno.2008.07.001. Epub 2008 Aug 8.

PMID:
18692224
18.

Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer.

McMeekin S, Patel R, Verschraegen C, Celano P, Burke J 2nd, Plaxe S, Ghatage P, Giurescu M, Stredder C, Wang Y, Schmelter T.

Br J Cancer. 2012 Jan 3;106(1):70-6. doi: 10.1038/bjc.2011.499. Epub 2011 Nov 22.

19.

Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer.

Taylor SE, Li R, Petschauer JS, Donovan H, O'Neal S, Keeler AW, Zamboni WC, Edwards RP, Zorn KK.

Gynecol Oncol. 2015 Sep;138(3):548-53. doi: 10.1016/j.ygyno.2015.06.026. Epub 2015 Jun 23.

PMID:
26111788
20.

Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer.

Tas F, Derin D, Guney N, Aydiner A, Topuz E.

Int J Clin Oncol. 2008 Aug;13(4):330-4. doi: 10.1007/s10147-007-0757-8. Epub 2008 Aug 15.

PMID:
18704633
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk